S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
Log in
NASDAQ:CYTH

Cyclo Therapeutics Stock Forecast, Price & News

$8.64
-0.41 (-4.53 %)
(As of 02/25/2021 02:21 PM ET)
Add
Compare
Today's Range
$8.42
Now: $8.64
$9.36
50-Day Range
$4.65
MA: $7.62
$13.33
52-Week Range
$3.55
Now: $8.64
$17.75
Volume2,337 shs
Average Volume1.41 million shs
Market Capitalization$14.69 million
P/E RatioN/A
Dividend YieldN/A
Beta-1
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTH
CUSIPN/A
CIKN/A
Phone386 418 8060
Employees5
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.01 million
Book Value$0.77 per share

Profitability

Net Income$-7,530,000.00
Net Margins-903.35%

Miscellaneous

Market Cap$14.69 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

140th out of 1,957 stocks

Industrial Organic Chemicals Industry

7th out of 38 stocks

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$8.64
-0.41 (-4.53 %)
(As of 02/25/2021 02:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cyclo Therapeutics (NASDAQ:CYTH) Frequently Asked Questions

Is Cyclo Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cyclo Therapeutics stock.
View analyst ratings for Cyclo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cyclo Therapeutics?

Wall Street analysts have given Cyclo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cyclo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for CYTH?

1 equities research analysts have issued 12 month price targets for Cyclo Therapeutics' shares. Their forecasts range from $25.00 to $25.00. On average, they expect Cyclo Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 189.4% from the stock's current price.
View analysts' price targets for Cyclo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cyclo Therapeutics' key executives?

Cyclo Therapeutics' management team includes the following people:
  • Mr. N. Scott Fine, CEO & Director (Age 64, Pay $479.58k)
  • Dr. Jeffrey L. Tate, COO, Chief Quality Officer & Director (Age 63, Pay $252.93k)
  • Dr. Sharon H. Hrynkow, Chief Scientific Officer, Sr. VP of Medical Affairs & Member of Scientific Advisory Board (Age 61, Pay $337.08k)
  • Mr. Joshua M. Fine, CFO & Sec. (Age 39)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 76)
  • Mr. Michael Eric Lisjak, Chief Regulatory Officer & Sr. VP of Bus. Devel. (Age 48)

Who are some of Cyclo Therapeutics' key competitors?

What is Cyclo Therapeutics' stock symbol?

Cyclo Therapeutics trades on the NASDAQ under the ticker symbol "CYTH."

Who are Cyclo Therapeutics' major shareholders?

Cyclo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.88%), Worth Venture Partners LLC (5.22%) and Jane Street Group LLC (1.64%). Company insiders that own Cyclo Therapeutics stock include Francis Patrick Ostronic and Markus Sieger.
View institutional ownership trends for Cyclo Therapeutics
.

Which major investors are buying Cyclo Therapeutics stock?

CYTH stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Worth Venture Partners LLC, and Jane Street Group LLC. Company insiders that have bought Cyclo Therapeutics stock in the last two years include Francis Patrick Ostronic, and Markus Sieger.
View insider buying and selling activity for Cyclo Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclo Therapeutics' stock price today?

One share of CYTH stock can currently be purchased for approximately $8.64.

How much money does Cyclo Therapeutics make?

Cyclo Therapeutics has a market capitalization of $14.69 million and generates $1.01 million in revenue each year.

How many employees does Cyclo Therapeutics have?

Cyclo Therapeutics employs 5 workers across the globe.

What is Cyclo Therapeutics' official website?

The official website for Cyclo Therapeutics is www.ctd-holdings.com.

Where are Cyclo Therapeutics' headquarters?

Cyclo Therapeutics is headquartered at 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653.

How can I contact Cyclo Therapeutics?

Cyclo Therapeutics' mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The company can be reached via phone at 386 418 8060 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.